According to the WHO, Antibiotic resistance is one of the biggest threats to global health, food security, and development today. Also, a growing number of infections such as pneumonia, tuberculosis, gonorrhoea, and salmonellosis are becoming harder to treat as the antibiotics used to treat them become less effective.
Let’s hope we can learn lessons from the Covid-19 pandemic - infectious organisms evolve constantly, so vigilance and pre-emptive action is required to maintain the tools we need to fight back.
A slight change from Erin Duffy, Chief of R&D @ CARB-X, she has given the mantle to Aleks Engel the Novo Repair Impact Fund. They have $165 million to invest in companies involved in discovering and the early-stage development of therapies targeting resistant microorganisms. Aleks is a heavy-weight in this space and is a positive advocate for changing the way innovation in this space is rewarded. We are really looking forward to hearing his views on how this space will evolve in the post COVID-era.
Aleks will be quizzing some of the most innovative biotech companies in the space from both Cambridge and Oxford, in addition we welcome Ken Bradley, the Global Head, Infectious Diseases from global big pharma @Roche who are one of the pioneers/leaders in this battle. This is a very exciting global panel and we look forward to a compelling and refreshing discussion.
Click Here to Register for the Webinar - https://us02web.zoom.us/webinar/register/9015904765382/WN_CwnjB-RpQveB3vsOh0Sz0g
Webinar Chair:
Aleks Engel, Partner, Novo Holdings (Novo Seeds) and Director, REPAIR Impact Fund at Novo Holdings
Panellists and Speakers:
Ken Bradley, Global Head, Infectious Disease Discovery at Roche pharmaceutical Research and Early Development (pRED)
Ankit Mahadevia, CEO of NASDAQ listed, Spero Therapeutics
Paul Finn, CEO of Oxford University Spinout, Oxford Drug Design
Ajay Mistry, CEO of AI and antibiotics discovery start-up, Oppilotech
